Literature DB >> 17016221

Clinical impact of obesity on stability following revision total hip arthroplasty.

Youjeong Kim1, Saam Morshed, Tim Joseph, Kevin Bozic, Michael D Ries.   

Abstract

Similar outcomes have been reported for obese and nonobese patients after primary total hip arthroplasty (THA), indicating obesity is not a contraindication to total hip arthroplasty. However, obese patients may develop implant failure and require revision THA. We compared the outcomes of revision THA in a matched cohort of obese and nonobese patients. Patients were stratified into two groups according to BMI (body mass index, kg/m2): Group 1 included 31 obese patients (BMI > 35), and Group 2 included 62 nonobese patients (BMI < 30) matched on age, gender, and type of revision procedure. Obese patients had increased total operating room time, a higher rate of discharge to a skilled nursing facility, and a higher dislocation rate (p < 0.05). Seven patients in the obese group underwent revision surgery, six of whom underwent additional reoperations to treat recurrent postoperative dislocation. Obese patients should be counseled about the increased risk of dislocation that can occur after revision THA.

Entities:  

Mesh:

Year:  2006        PMID: 17016221     DOI: 10.1097/01.blo.0000238874.09390.a1

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  24 in total

1.  A critical analysis of radiographic factors in patients who develop dislocation after elective primary total hip arthroplasty.

Authors:  Marion Opperer; Yuo-yu Lee; Francisco Nally; Alvaro Blanes Perez; Kaveh Goudarz-Mehdikhani; Alejandro Gonzalez Della Valle
Journal:  Int Orthop       Date:  2015-10-27       Impact factor: 3.075

2.  Obesity is associated with higher complication rates in revision total hip arthroplasty.

Authors:  John W Kennedy; David Young; Dominic R M Meek; Sanjeev R Patil
Journal:  J Orthop       Date:  2018-01-30

Review 3.  Impingement and dislocation in total hip arthroplasty: mechanisms and consequences.

Authors:  Thomas D Brown; Jacob M Elkins; Douglas R Pedersen; John J Callaghan
Journal:  Iowa Orthop J       Date:  2014

Review 4.  The evolution of outcomes and indications for the dual-mobility cup: a systematic review.

Authors:  Cécile Batailler; Camdon Fary; Régis Verdier; Thierry Aslanian; Jacques Caton; Sebastien Lustig
Journal:  Int Orthop       Date:  2016-12-21       Impact factor: 3.075

5.  Is an algorithmic approach to the treatment of recurrent dislocation after THA effective?

Authors:  Ehsan Saadat; Glenn Diekmann; Steven Takemoto; Michael D Ries
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

6.  Dual-mobility implants prevent hip dislocation following hip revision in obese patients.

Authors:  Philippe Hernigou; Jean Charles Auregan; Damien Potage; François Roubineau; Charles Henri Flouzat Lachaniette; Arnaud Dubory
Journal:  Int Orthop       Date:  2016-10-20       Impact factor: 3.075

7.  Morbid obesity may increase dislocation in total hip patients: a biomechanical analysis.

Authors:  Jacob M Elkins; Matej Daniel; Douglas R Pedersen; Bhupinder Singh; H John Yack; John J Callaghan; Thomas D Brown
Journal:  Clin Orthop Relat Res       Date:  2012-08-21       Impact factor: 4.176

8.  Outcomes of isolated acetabular revision.

Authors:  Bryan M Lawless; William L Healy; Sanjeev Sharma; Richard Iorio
Journal:  Clin Orthop Relat Res       Date:  2010-02       Impact factor: 4.176

9.  Dual-mobility or Constrained Liners Are More Effective Than Preoperative Bariatric Surgery in Prevention of THA Dislocation.

Authors:  Philippe Hernigou; Matthieu Trousselier; François Roubineau; Charlie Bouthors; Charles Henri Flouzat Lachaniette
Journal:  Clin Orthop Relat Res       Date:  2016-10       Impact factor: 4.176

10.  Obesity increases length of stay and direct medical costs in total hip arthroplasty.

Authors:  Hilal Maradit Kremers; Sue L Visscher; Walter K Kremers; James M Naessens; David G Lewallen
Journal:  Clin Orthop Relat Res       Date:  2013-10-08       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.